1. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor
- Author
-
Jones, LaQuita M., Melgar, Katelyn, Bolanos, Lyndsey, Hueneman, Kathleen, Walker, Morgan M., Jiang, Jian-Kang, Wilson, Kelli M., Zhang, Xiaohu, Shen, Jian, Jiang, Fan, Sutter, Patrick, Wang, Amy, Xu, Xin, Tawa, Gregory J., Hoyt, Scott B., Wunderlich Mark, O'Brien, Eric, Perentesis, John P., Starczynowski, Daniel T., and Thomas, Craig J.
- Subjects
Children's Hospital Medical Center ,Development and progression ,Genetic aspects ,Midostaurin ,Tyrosine -- Genetic aspects ,Gene mutation -- Genetic aspects ,Medical research ,Drug approval ,Antineoplastic agents ,Sorafenib ,Gilteritinib ,Acute myelocytic leukemia ,Clinical trials ,Phenols (Class of compounds) ,Myeloid leukemia ,Cabozantinib ,Diseases ,Ponatinib - Abstract
Introduction Acute myeloid leukemia (AML) is associated with mutations in FMS-like tyrosine kinase 3 (FLT3) in approximately 30% of cases, including internal tandem duplications (ITDs) and point mutations in the [...], Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like tyrosine kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML). We report a cocrystal structure of FLT3 with a type I inhibitor, NCGC1481, that retained potent binding and activity against FLT3 TKD and gatekeeper mutations. Relative to the current generation of advanced FLT3 inhibitors, NCGC1481 exhibited superior antileukemic activity against the common, clinically relevant FLT3-mutant AML cells in vitro and in vivo.
- Published
- 2020
- Full Text
- View/download PDF